Corinne Johnson
Stock Analyst at Goldman Sachs
(3.29)
# 1,069
Out of 5,116 analysts
16
Total ratings
57.14%
Success rate
18.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Maintains: Neutral | $18 → $28 | $26.16 | +7.03% | 2 | Dec 15, 2025 | |
| MBX MBX Biosciences | Initiates: Sell | $18 | $30.90 | -41.75% | 1 | Dec 4, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $12.33 | +62.21% | 2 | Sep 16, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $20 → $24 | $21.30 | +12.68% | 2 | Sep 5, 2025 | |
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $72.13 | -23.75% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $21.97 | +50.20% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $145.26 | +25.29% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $39.84 | +25.50% | 3 | May 14, 2024 |
Immunovant
Dec 15, 2025
Maintains: Neutral
Price Target: $18 → $28
Current: $26.16
Upside: +7.03%
MBX Biosciences
Dec 4, 2025
Initiates: Sell
Price Target: $18
Current: $30.90
Upside: -41.75%
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $12.33
Upside: +62.21%
Syndax Pharmaceuticals
Sep 5, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $21.30
Upside: +12.68%
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $72.13
Upside: -23.75%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $21.97
Upside: +50.20%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $145.26
Upside: +25.29%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $39.84
Upside: +25.50%